[Taisho Pharmaceutical, Lipobitan Noncaffeine 100mL]

A nourishing tonic perfect for those who are concerned about caffeine! Lipobitan non-caffeinated.
Lipobitan Non-Caffeine is a 100mL drink containing 1000mg of taurine and B vitamins per bottle.
It has excellent effects on physical fatigue, during and after illness, in nutrition supply, nourishment and tonicity, and weak constitution.
It is recommended for those suffering from febrile and wasting diseases such as a cold or for those who want to avoid caffeine intake before bedtime.


[Precautions for use]
<Consultation>
1. In the following cases, stop taking immediately and consult your doctor or pharmacist with the product.
(1) If the following symptoms appear after taking.
· Skin: Rash
Digestive: stomach discomfort
(2) When symptoms do not improve even after taking it for a while.

2. The following symptoms may appear, so if these symptoms persist or increase, stop taking the drug and consult your doctor or pharmacist.
diarrhea


[Efficacy effect]
Nutrient supplementation in case of physical fatigue, during illness, loss of appetite, nutritional disorder, febrile wasting disease, pregnancy or lactation period, etc.
· nourishing tonic
・Weak constitution


[Usage / Dosage]
Adults (over 15 years old), please take 1 bottle (100mL) once a day.
※Please do not take under the age of 15.


[Caution on usage]
Strictly adhere to the prescribed usage and dosage.
(When taking products containing other vitamins, etc. at the same time, be careful of excessive intake)


[Ingredient/Amount] in 1 bottle (100mL)
Taurine: 1000mg
Inositol: 50mg
Nicotinamide: 20mg
Thiamine Nitride: 5mg
Sodium Riboflavin Phosphate: 15mg
Pyridoxine Hydrochloride: 5mg


[additive]
Sucrose, D-sorbitol, citric acid, sodium benzoate, flavoring, glycerin, vanillin


[Precautions for storage and handling]
(1) Store in a cool place out of direct sunlight.
(2) Keep out of reach of children.
(3) Do not take products past the expiration date.

If there is no special information, the default shipping policy will be followed.